Skip to main content
SpringerLink
Log in

A case for Tamoxifen with ovarian function suppression

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Regan MM, Fleming GF, Walley B et al (2019) Adjuvant systemic treatment of premenopausal women with hormone receptor-positive early breast cancer: lights and shadows. J Clin Oncol 37:862–866

    Article  CAS  Google Scholar 

  2. Pagani O, Francis PA, Fleming GF et al (2020) Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT. J Clin Oncol 38:1293–1303

    Article  Google Scholar 

  3. Bellet M, Gray KP, Francis PA et al (2016) Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy. J Clin Oncol 34:1584–1593

    Article  CAS  Google Scholar 

  4. Dignam JJ, Wieand K, Johnson KA et al (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95:1467–1476

    Article  CAS  Google Scholar 

  5. Sestak I, Distler W, Forbes JF et al (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28:3411–3415

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Florida, 1600 SW Archer Road, PO Box 100278, Gainesville, FL, 32610, USA

    Pallavi Kopparthy & Karen Daily

Authors
  1. Pallavi Kopparthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen Daily
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karen Daily.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kopparthy, P., Daily, K. A case for Tamoxifen with ovarian function suppression. Breast Cancer Res Treat 183, 241–242 (2020). https://doi.org/10.1007/s10549-020-05766-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-020-05766-4

Search

Navigation